Joanna Góra‐Tybor
- Genetics top 1%
- Hematology top 2%
- Pathology and Forensic Medicine top 5%
- Molecular Biology
- Oncology
- Co-authors
- Tadeusz RobakMichael W. DeiningerJunia V. MeloJohn M. GoldmanShikha BoseJerzy Z. BłońskiMarek KasznickiKrzysztof Jamroziak
- Topics
- Chronic Lymphocytic Leukemia Research (46 papers)Chronic Myeloid Leukemia Treatments (33 papers)Lymphoma Diagnosis and Treatment (20 papers)
- Partner nations
- PolandGermanyUnited Kingdom
In The Last Decade
Joanna Góra‐Tybor
74 papers receiving 1.2k citations
Peers
Comparison fields: 5 of 76
- Genetics 733
- Hematology 594
- Pathology and Forensic Medicine 381
- Molecular Biology 291
- Oncology 218
Countries citing papers authored by Joanna Góra‐Tybor
This map shows the geographic impact of Joanna Góra‐Tybor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joanna Góra‐Tybor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joanna Góra‐Tybor more than expected).
Fields of papers citing papers by Joanna Góra‐Tybor
This network shows the impact of papers produced by Joanna Góra‐Tybor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joanna Góra‐Tybor. The network helps show where Joanna Góra‐Tybor may publish in the future.
Co-authorship network of co-authors of Joanna Góra‐Tybor
This figure shows the co-authorship network connecting the top 25 collaborators of Joanna Góra‐Tybor. A scholar is included among the top collaborators of Joanna Góra‐Tybor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joanna Góra‐Tybor. Joanna Góra‐Tybor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 3 | |
| 5 | 0 | |
| 6 | 3 | |
| 7 | 1 | |
| 8 | 30 | |
| 9 | 36 | |
| 10 | A european observational study of dasatinib in the management of imatinib-resistant and -intolerant patients with chronic myeloid leukemia: forte study (ca180-211) | 1 |
| 11 | 14 | |
| 12 | 22 | |
| 13 | 55 | |
| 14 | 14 | |
| 15 | 9 | |
| 16 | 10 | |
| 17 | 38 | |
| 18 | 32 | |
| 19 | 7 | |
| 20 | 1 |
About Joanna Góra‐Tybor
Joanna Góra‐Tybor is a scholar working on Genetics, Hematology and Pathology and Forensic Medicine, having authored 82 papers that have together received 1.2k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (46 papers), Chronic Myeloid Leukemia Treatments (33 papers) and Lymphoma Diagnosis and Treatment (20 papers). The work is most often cited by research in Genetics (733 citations), Hematology (594 citations) and Pathology and Forensic Medicine (381 citations). Joanna Góra‐Tybor has collaborated with scholars based in Poland, Germany and United Kingdom. Frequent co-authors include Tadeusz Robak, Michael W. Deininger, Junia V. Melo, John M. Goldman, Shikha Bose, Jerzy Z. Błoński, Marek Kasznicki, Krzysztof Jamroziak, Małgorzata Całbecka and L Konopka. Their work appears in journals such as Journal of Clinical Oncology, Blood and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.